81 related articles for article (PubMed ID: 20536463)
1. Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.
Grandini E; Cannoletta F; Scuteri A; Fortini C; Loggi E; Cursaro C; Riili A; Di Donato R; Gramenzi A; Bernardi M; Andreone P
Ann N Y Acad Sci; 2010 Apr; 1194():147-52. PubMed ID: 20536463
[TBL] [Abstract][Full Text] [Related]
2. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Camerini R; Ciancio A; DE Rosa A; Rizzetto M
Ann N Y Acad Sci; 2007 Sep; 1112():368-74. PubMed ID: 17600286
[TBL] [Abstract][Full Text] [Related]
3. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
[TBL] [Abstract][Full Text] [Related]
4. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
[TBL] [Abstract][Full Text] [Related]
5. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
Abbas Z; Hamid SS; Tabassum S; Jafri W
J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184
[TBL] [Abstract][Full Text] [Related]
6. Thymalfasin in the treatment of hepatitis B and C.
Ciancio A; Rizzetto M
Ann N Y Acad Sci; 2010 Apr; 1194():141-6. PubMed ID: 20536462
[TBL] [Abstract][Full Text] [Related]
7. Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi VK
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):885-92. PubMed ID: 16307501
[TBL] [Abstract][Full Text] [Related]
8. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.
Rustgi V
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S76-8. PubMed ID: 15546255
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.
Poo JL; Sánchez Avila F; Kershenobich D; García Samper X; Torress-Ibarra R; Góngora J; Cano C; Parada M; Uribe M
Ann Hepatol; 2008; 7(4):369-75. PubMed ID: 19034238
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
[TBL] [Abstract][Full Text] [Related]
12. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
13. Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi VK
Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
[TBL] [Abstract][Full Text] [Related]
15. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
[TBL] [Abstract][Full Text] [Related]
16. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19(12):S79-81. PubMed ID: 15641210
[TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir for previously treated chronic HCV infection.
McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
